Celldex Therapeutics
Clinical trials sponsored by Celldex Therapeutics, explained in plain language.
Biotech developing immunotherapies for cancer and other diseases.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New hope for chronic hives: barzolvolimab in Late-Stage trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New hope for chronic hive sufferers: drug shows promise in major trial Results expected Oct 2026 (estimated) 🚀 Make-or-break
- New asthma drug enters early human safety testing Results expected Mar 2027 (estimated)
-
New shot could ease swallowing for eosinophilic esophagitis patients
Disease control CompletedThis phase 2 trial tested a biologic drug called barzolvolimab in 86 adults with active eosinophilic esophagitis, a condition that causes trouble swallowing due to inflammation in the esophagus. Participants received either the drug or a placebo as a shot under the skin. The stud…
Phase 2 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:37 UTC
-
New shot could tame stubborn hives that antihistamines Can't stop
Disease control CompletedThis Phase 2 study tested a drug called barzolvolimab (CDX-0159) in 196 adults with chronic inducible urticaria—hives triggered by cold or scratching—that persist despite antihistamines. Participants received either the drug or a placebo as a shot under the skin. The main goal wa…
Phase 2 • Sponsor: Celldex Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug CDX-622 tested for safety in healthy people
Knowledge-focused CompletedThis completed Phase 1 trial tested the safety of a new drug called CDX-622 in 85 healthy adults aged 18-55. Participants received either CDX-622 or a placebo (saline) by infusion or injection. The study measured side effects, drug levels in the blood, and immune responses. Since…
Phase 1 • Sponsor: Celldex Therapeutics • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC